Multiple myeloma: Head-to-head ENDEAVOR study results demonstrate superiority of Kyprolis combination over Velcade combination

Amgen have announced that The Lancet Oncology published results from the pivotal Phase 3 head-to-head ENDEAVOR study comparing Kyprolis® (carfilzomib) plus dexamethasone to Velcade&reg… Source link